Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
Public ClinicalTrials.gov record NCT07169279. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 2b, Randomized, Double-Blind, Placebo-Controlled Clinical Trial, Preceded by a Single Ascending Dose Portion and a Phase 2 Open-Label Portion, to Evaluate the Safety and Efficacy of Oral Infigratinib in Infants and Young Children With Achondroplasia
Study identification
- NCT ID
- NCT07169279
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- QED Therapeutics, a BridgeBio company
- Industry
- Enrollment
- 77 participants
Conditions and interventions
Conditions
Interventions
- Infigratinib is provided as a single dose of minitablets for oral administration Drug
- Infigratinib is provided as sprinkle capsules for daily oral administration Drug
- Infigratinib or placebo comparator is provided as sprinkle capsules for daily oral administration Drug
Drug
Eligibility (public fields only)
- Age range
- 0 Years to 32 Months
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2025
- Primary completion
- Feb 29, 2032
- Completion
- Feb 29, 2032
- Last update posted
- May 11, 2026
2025 – 2032
United States locations
- U.S. sites
- 3
- U.S. states
- 3
- U.S. cities
- 3
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCSF Benioff Children's Hospital | Oakland | California | 94609 | Recruiting |
| Johns Hopkins University | Baltimore | Maryland | 21218 | Recruiting |
| University of Wisconsin Madison - Waisman Center Bone Dysplasia Clinic | Madison | Wisconsin | 53705 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 10 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07169279, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 11, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07169279 live on ClinicalTrials.gov.